CompletedNCT03097133
54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicide prevention, in Adult Participants Assessed to be at Imminent Risk for Suicide
This study evaluated the safety and effectiveness of Esketamine for people with depression.
Medication studyAges 18–64Multiple countries
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Esketamine for people with depression.
Who was this study for?
Listed age limits: 18 years to 64 years.
- Listed locations
- San Diego and 60 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: June 15, 2017
- Recruitment status
- Completed
- Enrollment listed in the registry
- 230
- Sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, France, Canada, ...
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT03097133
- Official title
Show the full official title
A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Subjects Assessed to be at Imminent Risk for Suicide
Get this study by email
Recruitment & locations
CompletedSan Diego, United States · Farmington, United States · Miami, United States
56 more locations
- North Miami, United States
- Tampa, United States
- Atlanta, United States
- Springfield, United States
- Winfield, United States
- Lake Charles, United States
- Baltimore, United States
- Las Vegas, United States
- Glen Oaks, United States
- Stony Brook, United States
- Chapel Hill, United States
- Cincinnati, United States
- Johnson City, United States
- Madison, United States
- Banfield, Argentina
- Ciudad de Buenos Aires, Argentina
- Córdoba, Argentina
- La Plata, Argentina
- Vienna, Austria
- Wels, Austria
- Bruges, Belgium
- Ghent, Belgium
- Lede, Belgium
- Belo Horizonte, Brazil
- Fortaleza, Brazil
- Itapira, Brazil
- Salvador, Brazil
- Santo André, Brazil
- São Paulo, Brazil
- Toronto, Canada
- Montreal, Canada
- Brno, Czechia
- Havířov, Czechia
- Klecany, Czechia
- Prague, Czechia
- Bohars, France
- Montpellier, France
- Nîmes, France
- Paris, France
- Saint-Priest-en-Jarez, France
- Toulouse, France
- Kaunas, Lithuania
- Kaunas County, Lithuania
- Vilnius, Lithuania
- Gdansk, Poland
- Gorlice, Poland
- Lodz, Poland
- Pruszków, Poland
- Barcelona, Spain
- Bilbao, Spain
- Pamplona, Spain
- Bursa, Türkiye
- Istanbul, Türkiye
- Samsun, Türkiye
- Czechia
- Türkiye
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of Esketamine for people with depression.
Who is behind this study?
The study sponsor is Janssen Research & Development, LLC.
Did this study involve medication?
Yes. The study involved medication, including Esketamine and Placebo.
Who was this study for?
Listed age limits: 18 years to 64 years.
Want to find a study that may fit you better?
Explore HopeStage studies by mental health topic and refine the results to suit your situation.
Find a study that may fit meRelated studies
54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicide prevention, in Adult Participants Assessed to be at Imminent Risk for Suicide
A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicide prevention, in Participants Who Are Assessed to be at Imminent Risk for Suicide